TNFRSF12A Antikörper (PE)
-
- Target Alle TNFRSF12A Antikörper anzeigen
- TNFRSF12A (Tumor Necrosis Factor Receptor Superfamily, Member 12A (TNFRSF12A))
-
Reaktivität
- Human, Maus
-
Wirt
- Maus
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser TNFRSF12A Antikörper ist konjugiert mit PE
-
Applikation
- Flow Cytometry (FACS)
- Spezifität
- The mouse monoclonal antibody ITEM-4 recognizes an extracellular epitope of CD266 / TWEAK R, a TNFR superfamily receptor for CD255 / TWEAK, a TNF-like weak inducer of apoptosis.
- Kreuzreaktivität (Details)
- Human, Mouse
- Aufreinigung
- Purified antibody is conjugated with R-phycoerythrin (PE) under optimum conditions. Unconjugated antibody and free fluorochrome are removed by size-exclusion chromatography.
- Immunogen
- human CD266-transfected P815 cells
- Klon
- ITEM-4
- Isotyp
- IgG2b
- Top Product
- Discover our top product TNFRSF12A Primärantikörper
-
-
- Applikationshinweise
- Flow cytometry: Recommended dilution: 2-4 μg/mL.
- Kommentare
-
The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Konzentration
- 0.1 mg/mL
- Buffer
- Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- Konservierungsmittel
- Sodium azide
- Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- 4 °C
- Informationen zur Lagerung
- Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.
-
-
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
: "Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 185, Issue 3, pp. 1593-605, (2010) (PubMed).
: "Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 1, pp. 341-8, (2002) (PubMed).
: "
-
Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer." in: Experimental and therapeutic medicine, Vol. 2, Issue 1, pp. 103-108, (2012) (PubMed).
-
- Target
- TNFRSF12A (Tumor Necrosis Factor Receptor Superfamily, Member 12A (TNFRSF12A))
- Andere Bezeichnung
- CD266 / TWEAK R (TNFRSF12A Produkte)
- Hintergrund
- TNF receptor superfamily member 12A,CD266 / TWEAK R (TNFRSF12A), also known as FN14 (fibroblast growth factor-inducible 14) is a receptor for CD255 / TWEAK, the TNF-like weak inducer of apoptosis. CD266 is expressed on endothelial cells, as well as on some cancer tissues, and plays a role in CD255-induced endothelial cell migration, proliferation, and angiogenesis. The CD255-CD266 interaction, or antibody-mediated triggering of CD266 is also able to induce apoptosis and necrosis in CD266-positive cells (including tumor cells), which might have therapeutic potential.,TWEAKR, FN14, TNFRSF12A
- Gen-ID
- 51330
- UniProt
- Q9NP84
- Pathways
- Apoptose, Regulation of Cell Size
-